MIRA Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About MIRA
All events for MIRA
All deals for MIRA
Financial Ratios
Financial Statements
MIRA vs Sector & Peers
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland. Website mirapharmaceuticals.com
Headquarters Miami, FL, US